Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Merck & Co., Inc. operates as a healthcare company ... The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology ...

Merck 2025 Sales Forecast Underwhelms as It ... forecast due partly to a pause in shipments of one of its top-selling products to China. The drugmaker plans to temporarily pause shipments of ...

Merck MRK0.16%increase; green up pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...

Merck (MRK) announced that the European Commission has conditionally approved WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other dividend stocks. Dividend stocks, while popular ... Morningstar's director of product ...